Active Surveillance as First-Line Management of Papillary Microcarcinoma

Literature Cited

1. 1.  Ito Y, Miyauchi A 2007. A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. Nat. Clin. Pract. Endocrinol. Metab. 3:3240–48
   [Google Scholar]
2. 2.  Takebe K, Date M, Yamamoto N 1994. 超音波を用いた甲状腺癌検診の実際とその問題点. [Mass screening for thyroid cancer with ultrasonography.]. Karkinos 7:309–17
   [Google Scholar]
3. 3.  Ito Y, Miyauchi A, Oda H et al. 2016. Revisiting low-risk thyroid papillary microcarcinomas resected without observation: Was immediate surgery necessary?. World J. Surg. 40:3523–28
   [Google Scholar]
4. 4.  Davies L, Welch HG 2006. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:182164–67
   [Google Scholar]
5. 5.  Davies L, Welch HG 2014. Current thyroid cancer trends in the United States. JAMA Otolaryngol. Head Neck Surg. 140:4217–22
   [Google Scholar]
6. 6.  Ahn HS, Kim HJ, Welch HG 2014. Korea's thyroid-cancer “epidemic”—screening and overdiagnosis. N. Engl. J. Med. 371:191765–67
   [Google Scholar]
7. 7.  Vaccarella S, Franceschi S, Bray F et al. 2016. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N. Engl. J. Med. 375:7614–17
   [Google Scholar]
8. 8.  Oda H, Miyauchi A, Ito Y et al. 2016. Incidences of unfavorable events in the management of low-risk papillary microcarcinoma of the thyroid by active surveillance versus immediate surgery. Thyroid 26:1150–58
   [Google Scholar]
9. 9.  Takami H, Ito Y, Okamoto T et al. 2011. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J. Surg. 35:1111–21
   [Google Scholar]
10. 10.  Haugen BR, Alexander EK, Bible KC et al. 2016. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:11–133
    [Google Scholar]
11. 11.  Ito Y, Miyauchi A, Kudo T et al. 2018. Trends in the implementation of active surveillance for low-risk papillary thyroid microcarcinomas at Kuma Hospital: gradual increase and heterogeneity in the acceptance of this new management option. Thyroid 28:4488–95
    [Google Scholar]
12. 12.  Ito Y, Uruno T, Nakano K et al. 2003. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:4381–87
    [Google Scholar]
13. 13.  Uruno T, Miyauchi A, Shimizu K et al. 2005. Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. World J. Surg. 29:4483–86
    [Google Scholar]
14. 14.  Ito Y, Tomoda C, Uruno T et al. 2004. Papillary microcarcinoma of the thyroid: How should it be treated?. World J. Surg. 28:5498–501
    [Google Scholar]
15. 15.  Ito Y, Miyauchi A, Inoue H et al. 2010. An observation trial for papillary thyroid microcarcinoma in Japanese patients. World J. Surg. 34:128–35
    [Google Scholar]
16. 16.  Ito Y, Miyauchi A, Kihara M et al. 2014. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 24:127–34
    [Google Scholar]
17. 17.  Ito Y, Miyauchi A, Kihara M et al. 2018. Overall survival of papillary thyroid carcinoma patients: a single institution long-time follow-up of 5897 patients. World J. Surg. 42:3615–22
    [Google Scholar]
18. 18.  Miyauchi A, Kudo T, Ito Y et al. 2018. Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. Surgery 163:148–52
    [Google Scholar]
19. 19.  Sugitani I, Toda K, Yamada K et al. 2010. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J. Surg. 34:61222–31
    [Google Scholar]
20. 20.  Fukuoka O, Sugitani I, Ebina A et al. 2016. Natural history of asymptomatic papillary thyroid microcarcinoma: time-dependent changes in calcification and vascularity during active surveillance. World J. Surg. 40:3529–37
    [Google Scholar]
21. 21.  Sugitani I, Fujimoto Y, Yamada K 2014. Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. World J. Surg. 38:3673–78
    [Google Scholar]
22. 22.  Shindo H, Amino N, Ito Y et al. 2014. Papillary thyroid microcarcinoma might progress during pregnancy. Thyroid 24:5840–44
    [Google Scholar]
23. 23.  Ito Y, Miyauchi A, Kudo T et al. 2016. Effects of pregnancy on papillary microcarcinoma of the thyroid re-evaluated in the entire patient series at Kuma Hospital. Thyroid 26:1156–60
    [Google Scholar]
24. 24.  Oda H, Miyauchi A, Ito Y et al. 2017. Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid. Endocr. J 64:159–64
    [Google Scholar]
25. 25.  Brito JP, Ito Y, Miyauchi A et al. 2016. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid 26:1144–49
    [Google Scholar]
26. 26.  Nickel B, Brito JP, Barratt A et al. 2017. Clinicians’ view on management and terminology for papillary thyroid microcarcinoma: a qualitative study. Thyroid 27:5661–71
    [Google Scholar]
27. 27.  Nickel B, Brito JP, Moynihan R et al. 2018. Patients’ experiences of diagnosis and management of papillary thyroid microcarcinoma: a qualitative study. BMC Cancer 18:1242
    [Google Scholar]
28. 28.  Tuttle RM, Fagin JA, Minkowitz G et al. 2017. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol. Head Neck Surg. 143:101015–20
    [Google Scholar]
29. 29.  Kwon H, Oh HS, Kim M et al. 2017. Active surveillance for patients with papillary thyroid microcarcinoma: a single center's experience in Korea. J. Clin. Endocrinol. Metab. 102:61917–25
    [Google Scholar]
30. 30.  Kim HI, Jang HW, Ahn HS et al. 2018. High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance. J. Clin. Endocrinol. Metab. 103:2446–51
    [Google Scholar]
31. 31.  Yabuta T, Matsuse M, Hirokawa M et al. 2017. TERT promoter mutations were not found in papillary thyroid microcarcinomas that showed disease progression on active surveillance. Thyroid 27:91206–7
    [Google Scholar]
32. 32.  Xing A, Liu R, Liu X et al. 2014. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J. Clin. Oncol. 32:252718–26
    [Google Scholar]
33. 33.  Hirokawa M, Kudo T, Ota H et al. 2016. Pathological characteristics of low-risk papillary thyroid microcarcinoma with progression during active surveillance. Endocr. J 63:9805–10
    [Google Scholar]
34. 34.  Miyauchi A 2016. Clinical trials of active surveillance of papillary microcarcinoma of the thyroid. World J. Surg. 40:1516–22
    [Google Scholar]
35. 35.  Miyauchi A, Ito Y, Oda H 2018. Insights into the management of papillary microcarcinoma of the thyroid. Thyroid 28:123–31
    [Google Scholar]